Table 2. The association of the chemotherapy related incident ocular diseases with the risk of incident composite endpoint (major adverse cardiovascular events, including all individuals), and its individual components.
| Ocular diseases (n = 483) | No ocular diseases (n = 1651) | p value | |
| Composite endpoints | |||
| No. of events (%)/total patients | 72 (36.36)/198 | 224 (20.70)/1082 | |
| Crude RR (95% CI) | 1.76 (1.35-2.29) | 1.00 | < 0.0001* |
| Adjusted RR (95% CI) | 1.18 (0.88-1.58) | 1.00 | 0.2682 |
| Prior event or clinic visits < 3 | 285 | 569 | |
| Myocardial infarction | |||
| No. of events (%)/total patients | 2 (0.42)/474 | 4 (0.24)/1639 | |
| Crude RR (95% CI) | 1.73 (0.32-9.44) | 1.00 | 0.5273 |
| Adjusted RR (95% CI) | 0.62 (0.11-3.53) | 1.00 | 0.5854 |
| Prior event or clinic visits < 3 | 9 | 12 | |
| Congestive heart failure | |||
| No. of events (%)/total patients | 16 (3.78)/423 | 26 (1.63)/1592 | |
| Crude RR (95% CI) | 2.32 (1.24-4.32) | 1.00 | 0.0082* |
| Adjusted RR (95% CI) | 0.92 (0.48-1.76) | 1.00 | 0.8013 |
| Prior event or clinic visits < 3 | 60 | 59 | |
| Stroke (cerebrovascular disease) | |||
| No. of events (%)/total patients | 50 (13.44)/372 | 61 (3.99)/1528 | |
| Crude RR (95% CI) | 3.37 (2.32-4.89) | 1.00 | < 0.0001* |
| Adjusted RR (95% CI) | 1.81 (1.21-2.71) | 1.00 | 0.0036* |
| Prior event or clinic visits < 3 | 111 | 123 | |
| Dementia | |||
| No. of events (%)/total patients | 18 (3.89)/463 | 13 (0.80)/1632 | |
| Crude RR (95% CI) | 4.88 (2.39-9.96) | 1.00 | < 0.0001* |
| Adjusted RR (95% CI) | 2.20 (1.07-4.54) | 1.00 | 0.0329* |
| Prior event or clinic visits < 3 | 20 | 19 | |
| Hemiplegia or paraplegia | |||
| No. of events (%)/total patients | 3 (0.63)/479 | 3 (0.18)/1642 | |
| Crude RR (95% CI) | 3.43 (0.69-16.98) | 1.00 | 0.1313 |
| Adjusted RR (95% CI) | 1.64 (0.3-9.12) | 1.00 | 0.5717 |
| Prior event or clinic visits < 3 | 4 | 9 | |
| Renal Disease | |||
| No. of events (%)/total patients | 24 (5.87)/409 | 46 (2.96)/1552 | |
| Crude RR (95% CI) | 1.98 (1.21-3.24) | 1.00 | 0.0067* |
| Adjusted RR (95% CI) | 1.11 (0.66-1.88) | 1.00 | 0.6851 |
| Prior event or clinic visits < 3 | 74 | 99 | |
| End-stage renal disease | |||
| No. of events (%)/total patients | 4 (0.83)/481 | 7 (0.43)/1644 | |
| Crude RR (95% CI) | 1.95 (0.57-6.67) | 1.00 | 0.2855 |
| Adjusted RR (95% CI) | 1.14 (0.31-4.23) | 1.00 | 0.8464 |
| Prior event or clinic visits < 3 | 2 | 7 | |
| Peripheral vascular disease | |||
| No. of events (%)/total patients | 5 (1.10)/456 | 12 (0.75)/1604 | |
| Crude RR (95% CI) | 1.47 (0.52-4.16) | 1.00 | 0.4722 |
| Adjusted RR (95% CI) | 0.69 (0.23-2.05) | 1.00 | 0.4995 |
| Prior event or clinic visits < 3 | 27 | 47 |
* p < 0.05. Adjusted relative risk (RR) with 95% confidence intervals (CI) and their p values were calculated after adjustment for age on chemotherapy, sex, hypertension, diabetes mellitus and radiotherapy by using Cox proportional hazards regression model.
Note: In order not to sacrifice some temporal related specific event regarding to chemotherapy with ocular diseases (e.g., stroke), the exclusions for each endpoint of prior events or clinic visits < 3 were performed in this step.